^
    2d
    IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • citoplurikin (IRX-2)
    11d
    Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab). (PubMed, Cancer Res Commun)
    No synergistic toxicity was observed with combination treatment. Similar durability in immunogenicity was found with or without varlilumab. Depletion of circulating CD4+ T cells with varlilumab may have abrogated benefits of inducing tumor-cognate CD4+ T cells with vaccination. Induction of memory responses supports further work to optimize shared antigen vaccines in combination with other immunotherapies.
    P1/2 data • Journal
    |
    CD4 (CD4 Molecule) • CD27 (CD27 Molecule)
    |
    varlilumab (CDX 1127)
    19d
    Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies (clinicaltrials.gov)
    P1, N=42, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    CD30 biAb-AATC • Leukine (sargramostim)
    2ms
    A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (clinicaltrials.gov)
    P1, N=25, Terminated, Imugene Limited | N=50 --> 25 | Trial completion date: May 2029 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2027 --> Feb 2026; Portfolio prioritization
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Blincyto (blinatumomab) • hydroxyurea • VAXinia (CF33-hNIS) • onCARlytics (CF33-CD19)
    2ms
    MAST: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=66, Terminated, Imugene Limited | N=100 --> 66 | Trial completion date: Nov 2026 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2026; Portfolio prioritization
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • VAXinia (CF33-hNIS)
    3ms
    Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC (clinicaltrials.gov)
    P1, N=16, Terminated, Rutgers, The State University of New Jersey | Active, not recruiting --> Terminated; accrual goal met
    Trial termination
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD27 (CD27 Molecule)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Tecentriq (atezolizumab) • varlilumab (CDX 1127)
    3ms
    OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    BS001 • BS006
    3ms
    A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=400, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • etoposide IV • AiRuiLi (adebrelimab)
    3ms
    ACT: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, AgonOx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
    |
    AGX-148
    3ms
    NWRD06 DNA Plasmid for HCC After Curative Resection. (clinicaltrials.gov)
    P2, N=30, Recruiting, Newish Technology (Beijing) Co., Ltd.
    New P2 trial
    |
    GPC3 (Glypican 3)
    4ms
    MAST: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Imugene Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • VAXinia (CF33-hNIS)
    4ms
    NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways. (PubMed, J Immunother Cancer)
    These findings were validated in an immunocompetent B-cell lymphoma mouse model, where NX-1607 consistently upregulated PLCγ1 and ERK phosphorylation. Together, this work delineates a PLCγ1-MAPK/ERK axis through which Cbl-b inhibition unleashes T cell activation, providing critical insight for the development of NX-1607 based immunotherapy.
    Journal • IO biomarker
    |
    CD69 (CD69 Molecule)
    |
    NX-1607